Tags

Type your tag names separated by a space and hit enter

Antihypertensive and lipid lowering treatment in stroke prevention: current state and future.
Acta Neurol Belg. 2005 Jun; 105(2):57-61.AN

Abstract

Diabetes mellitus, arterial hypertension, smoking are major stroke risk factors. The role of hypercholesterolemia in stroke has not been established yet. In patients with type 2 diabetes mellitus there is evidence that intensive glucose lowering therapy diminishes the risk of microvascular complications. In all patients with stroke or transient ischemic attack (TIA), blood pressure should be lowered irrespectively of the baseline level with either diuretics, angiotensin converting enzyme (ACE) inhibitors, beta-blockers, or calcium antagonists. The role of angiotensin II (AT2) receptor blockers has not been established so far. In general terms a global approach to management of patients with vascular risk factors should be developed. An extended follow-up of randomised trials on preventive therapy should be completed. Controlled trials comparing angiotensin receptor blockers with ACE inhibitors should be started. Further research may focus on the new lipid lowering agents, and on the comparison of single lipid lowering agent vs. combinations in stroke prevention. These efforts should help in finding the best vasoprotective strategy in stroke prevention.

Authors+Show Affiliations

Department of Neurology, CHUV, Lausanne, Switzerland. bpiechow@amwaw.edu.plNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

16076057

Citation

Piechowski-Jóźwiak, Bartłomiej, and Julien Bogousslavsky. "Antihypertensive and Lipid Lowering Treatment in Stroke Prevention: Current State and Future." Acta Neurologica Belgica, vol. 105, no. 2, 2005, pp. 57-61.
Piechowski-Jóźwiak B, Bogousslavsky J. Antihypertensive and lipid lowering treatment in stroke prevention: current state and future. Acta Neurol Belg. 2005;105(2):57-61.
Piechowski-Jóźwiak, B., & Bogousslavsky, J. (2005). Antihypertensive and lipid lowering treatment in stroke prevention: current state and future. Acta Neurologica Belgica, 105(2), 57-61.
Piechowski-Jóźwiak B, Bogousslavsky J. Antihypertensive and Lipid Lowering Treatment in Stroke Prevention: Current State and Future. Acta Neurol Belg. 2005;105(2):57-61. PubMed PMID: 16076057.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Antihypertensive and lipid lowering treatment in stroke prevention: current state and future. AU - Piechowski-Jóźwiak,Bartłomiej, AU - Bogousslavsky,Julien, PY - 2005/8/4/pubmed PY - 2005/9/1/medline PY - 2005/8/4/entrez SP - 57 EP - 61 JF - Acta neurologica Belgica JO - Acta Neurol Belg VL - 105 IS - 2 N2 - Diabetes mellitus, arterial hypertension, smoking are major stroke risk factors. The role of hypercholesterolemia in stroke has not been established yet. In patients with type 2 diabetes mellitus there is evidence that intensive glucose lowering therapy diminishes the risk of microvascular complications. In all patients with stroke or transient ischemic attack (TIA), blood pressure should be lowered irrespectively of the baseline level with either diuretics, angiotensin converting enzyme (ACE) inhibitors, beta-blockers, or calcium antagonists. The role of angiotensin II (AT2) receptor blockers has not been established so far. In general terms a global approach to management of patients with vascular risk factors should be developed. An extended follow-up of randomised trials on preventive therapy should be completed. Controlled trials comparing angiotensin receptor blockers with ACE inhibitors should be started. Further research may focus on the new lipid lowering agents, and on the comparison of single lipid lowering agent vs. combinations in stroke prevention. These efforts should help in finding the best vasoprotective strategy in stroke prevention. SN - 0300-9009 UR - https://www.unboundmedicine.com/medline/citation/16076057/Antihypertensive_and_lipid_lowering_treatment_in_stroke_prevention:_current_state_and_future_ L2 - https://medlineplus.gov/cholesterolmedicines.html DB - PRIME DP - Unbound Medicine ER -